St. Jude Medical (NYSE:STJ) said the FDA approved its MultiPoint pacing technology for its Quadra Allure defibrillators and pacemakers, plus a new set of quadripolar pacing leads called Quartet LV.
The Little Canada, Minn.-based medical device company said the MultiPoint tech is the 1st to hit the U.S. market that allows physicians to tailor pacing therapy by controlling multiple pulses to the left ventricle for each heartbeat. Each lead in the system can deliver 2 pulses per heartbeat, St. Jude said.
The new Quartet LV leads have more electrode spacing options and a new, S-curved design, the company said.
“Continuing our quadripolar leadership, MultiPoint pacing represents our commitment to invest and innovate in state of the art heart failure treatment options,” chief technology officer Philip Ebeling said in prepared remarks. “These additions to our comprehensive CRT portfolio are examples of St. Jude Medical’s focus on providing physicians with technologies that result in effective patient outcomes and transform the treatment of some of the world’s most expensive epidemic diseases.”
“Having the ability to truly individualize cardiac resynchronization therapy is a significant step forward in the clinical approach to treating some of our most complex heart failure patients,” added Dr. Gery Tomassoni of Baptist Health Lexington in Lexington, Ky. “MultiPoint pacing technology provides a new set of tools that can be non-invasively programmed in an attempt to improve CRT response, thus opening up an important new treatment option for many patients who may need it.”
